COMMUNIQUÉS West-GlobeNewswire

Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
23/12/2025
PYLCLARI ® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, has announced that [...]
CancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025
23/12/2025
Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific Leadership Lehi, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, December 23, 2025 - CancerVax, Inc., the [...]
Burning Rock Announces Results of 2025 Annual General Meeting
23/12/2025
GUANGZHOU, China, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “ Company ” or “ Burning Rock ”), a company focusing on the application of next generation sequencing (NGS) technology [...]
Vireo Growth Inc. Enters California and Florida and Strengthens Delivery Platforms with Acquisition of Eaze Inc.
23/12/2025
Transaction will expand Vireo’s operating footprint to 10 states with 166 dispensaries and approximately 800,000 sq. ft. of cultivation and production Acquisition also will add an incremental 14 dispensaries to Company’ [...]
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
23/12/2025
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first [...]
Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique
23/12/2025
Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a [...]
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
23/12/2025
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by [...]
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
23/12/2025
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume for "Sermorelin Alternative" Climbs 340% Year-Over-Year NEW [...]
TOMI Environmental Solutions Expands Footprint in Cell and Gene Therapy Sector with Multi-Stage SteraMist iHP Implementation at a New Pharmaceutical Manufacturing Site
22/12/2025
FREDERICK, Md., Dec. 22, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today that a leading Cell and Gene [...]
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
22/12/2025
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the 44 th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The [...]
Apollomics Reports First Half 2025 Financial Results
22/12/2025
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
RxSight, Inc. Announces Chief Financial Officer Transition
22/12/2025
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22/12/2025
Wegovy ® pill showed a mean weight loss of 16.6% in the OASIS 4 trial 1 Wegovy ® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse [...]
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
23/12/2025
Analysis Examines GlucoBooster GLP-1 Gummies and Akkermansia-Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and Evidence Gaps Explained New York, Dec. 22, 2025 ( [...]
Vystar® Reports, Following its First of its Kind Court Victory against EMA Financial, Inc. of $497,439.58 in Legal Fees and Costs Awarded.
22/12/2025
Worcester, MA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar ® is proud to report; Following its first of its kind court victory on behalf of Vystar Corp. (“Vystar”) against EMA Financial, [...]
Alvotech’s Financial Calendar for 2026
22/12/2025
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the [...]
Celularity Announces Closing of Financing Transactions
22/12/2025
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the [...]
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
22/12/2025
Approvals expand Amneal’s biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“ [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/12/2025
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on [...]

Pages